Histone deacetylase inhibitors in the generation of the anti-tumour immune response (Q37953826)

25 August 2017

Histone deacetylase inhibitors in the generation of the anti-tumour immune response (English)

1 reference

25 August 2017

1

1 reference

25 August 2017

Brian Gabrielli

2

1 reference

25 August 2017

8 November 2011

1 reference

Immunology & Cell Biology

25 August 2017

1 reference

25 August 2017

90

1 reference

25 August 2017

1

1 reference

25 August 2017

33-38

1 reference

Anticancer activities of histone deacetylase inhibitors

25 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone deacetylase inhibitors: current status and overview of recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone deacetylases as regulators of inflammation and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Modulating molecular chaperone Hsp90 functions through reversible acetylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone deacetylase inhibitors specifically kill nonproliferating tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

The EBNA-3 gene family proteins disrupt the G2/M checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Natural innate and adaptive immunity to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Cellular immunotherapy for cancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Alterations in the apoptotic machinery and their potential role in anticancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Apoptosis or necrosis for tumor immunotherapy: what's in a name?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Death-defying immunity: do apoptotic cells influence antigen processing and presentation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

HMGB1 is an endogenous immune adjuvant released by necrotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Armed response: how dying cells influence T-cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

An epigenetically altered tumor cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

An epigenetic vaccine model active in the prevention and treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Structure-function studies for the panacea, valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Function of histone deacetylase inhibitors in inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Molecular Pathways Linking Inflammation and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Deacetylase inhibition promotes the generation and function of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Deacetylase inhibitor trichostatin A down-regulates Foxp3 expression and reduces CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Th2-mediated anti-tumour immunity: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Trichostatin-A enhances adaptive immune responses to DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

7 January 2021

Histone deacetylase inhibitors induce mitotic slippage

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

7 January 2021

Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints.

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

7 January 2021

Therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

7 January 2021

Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

7 January 2021

Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications

1 reference

https://api.crossref.org/works/10.1038%2FICB.2011.94

7 January 2021

Identifiers

DOI

10.1038/ICB.2011.94

1 reference

release_wrirxeaorfcexjxxwkdoyqbofu

25 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wrirxeaorfcexjxxwkdoyqbofu

24 November 2022

mapped directly with Wikidata item

PubMed ID

22064708

1 reference

PubMed ID

22064708